Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin.
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Capecitabine
/ administration & dosage
Colorectal Neoplasms
/ blood
Female
Fluorouracil
/ administration & dosage
Humans
Incidence
Leucovorin
/ administration & dosage
Logistic Models
Male
Middle Aged
Organoplatinum Compounds
/ administration & dosage
Oxaliplatin
/ administration & dosage
Oxaloacetates
/ administration & dosage
Peripheral Nervous System Diseases
/ blood
Retrospective Studies
Vitamin D
/ blood
Gastrointestinal system cancers
Oxaliplatin
Peripheral neuropathy
Toxicity
Treatment
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
21
11
2019
accepted:
17
01
2020
pubmed:
25
1
2020
medline:
23
10
2020
entrez:
25
1
2020
Statut:
ppublish
Résumé
We aimed to identify potential clinical parameters that can be easily obtained by a pre-treatment clinicopathological evaluation and whole blood test to estimate the development of oxaliplatin-induced peripheral neuropathy (OIPN). This study was conducted retrospectively. For the FOLFOX regimen, patients received oxaliplatin, 85 mg/m A total of 186 patients were included in the study. There were 108 (58%) patients in the grade 0-1 (G0-G1) neuropathy group (mean age 50.5 ± 11.5; 63% men), and 78 (42%) patients in the grade 2-3 (G2-G3) neuropathy group (mean age 58.0 ± 10.8; 46.2% men). The relationship between G2-G3 OIPN development and age (p < 0.001), gender (p = 0.02), and ECOG performance status (p = 0.007) was statistically significant. In the G2-G3 neuropathy group, serum gamma-glutamyl transferase (GGT) (p < 0.001) and glucose (p = 0.007) levels were higher, whereas vitamin D (p < 0.001), hemoglobin (Hgb) (p < 0.001), serum albumin (p = 0.001), and serum magnesium (p = 0.035) levels were lower compared with the G0-G1 neuropathy group. G2-G3 neuropathy was observed in 88% of patients with mucinous carcinoma pathologic type (p < 0.001). This study demonstrated that age, histopathologic type, albumin, GGT, glucose, vitamin D, and Hgb levels were the effective factors in prediction of the development of OIPN. In addition, GGT, vitamin D, and Hgb levels were the most effective factor to predict development of OIPN.
Identifiants
pubmed: 31974772
doi: 10.1007/s00520-020-05319-x
pii: 10.1007/s00520-020-05319-x
doi:
Substances chimiques
Organoplatinum Compounds
0
Oxaloacetates
0
Oxaliplatin
04ZR38536J
Vitamin D
1406-16-2
Capecitabine
6804DJ8Z9U
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4781-4788Références
Kim DY, Kim JH, Lee S-H, Kim TY, Heo DS, Bang YJ, Kim NK (2003) Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol 14(3):383–387. https://doi.org/10.1093/annonc/mdg106
doi: 10.1093/annonc/mdg106
pubmed: 12598342
Scagliotti GV, Kortsik C, Dark GG et al (2005) Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 11(2 Pt 1):690–696
pubmed: 15701857
Vincenzi B, Frezza AM, Schiavon G, Spoto C, Silvestris N, Addeo R, Catalano V, Graziano F, Santini D, Tonini G (2013) Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer 21(5):1313–1319. https://doi.org/10.1007/s00520-012-1667-5
doi: 10.1007/s00520-012-1667-5
pubmed: 23196819
André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351. https://doi.org/10.1056/ NEJMoa032709
Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M (2014) Incidence, prevalence, and predictors of chemotherapyinduced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461–2470. https://doi.org/10.1016/j.pain.2014.09.020
doi: 10.1016/j.pain.2014.09.020
pubmed: 25261162
Briani C, Argyriou AA, Izquierdo C et al (2014) Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. J Peripher Nerv Syst 19(4):299–306
doi: 10.1111/jns.12097
Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y (2013) Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer 21(12):3307–3313
doi: 10.1007/s00520-013-1905-5
Comella P, Lorusso V, Maiorino L, Casaretti R, Cannone M, Massidda B, Putzu C, Leo S, Roselli M, Mancarella S, Palmeri S, Greco E, Vessia G, Sandomenico C, Franco L (2009) Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group. Cancer Chemother Pharmacol 64(5):893–899
doi: 10.1007/s00280-009-0938-4
Giacchetti S, Perpoint B, Zidani R, le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, le Rol A, Walter S, Adam R, Misset JL, Lévi F (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18(1):136–147
doi: 10.1200/JCO.2000.18.1.136
Altaf R, Lund Brixen A, Kristensen B, Nielsen SE (2014) Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer. Oncology 87(3):167–172
doi: 10.1159/000362668
Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, de Gramont A (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer–a GERCOR study. J Clin Oncol 24(3):394–400
doi: 10.1200/JCO.2005.03.0106
Velasco R, Bruna J, Briani C et al (2014) Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry 85(4):392–398
doi: 10.1136/jnnp-2013-305334
Alejandro LM, Behrendt CE, Chen K, Openshaw H, Shibata S (2013) Predicting acute and persistent neuropathy associated with oxaliplatin. Am J Clin Oncol 36(4):331–337
doi: 10.1097/COC.0b013e318246b50d
Attal N, Bouhassira D, Gautron M, Vaillant JN, Mitry E, Lepère C, Rougier P, Guirimand F (2009) Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain 144(3):245–252
doi: 10.1016/j.pain.2009.03.024
Won HH, Lee J, Park JO, Park YS, Lim HY, Kang WK, Kim JW, Lee SY, Park SH (2012) Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer 118(11):2828–2836
doi: 10.1002/cncr.26614
Shahriari-Ahmadi A, Fahimi A, Payandeh M, Sadeghi M (2015) Prevalence of oxaliplatin-induced chronic neuropathy and influencing factors in patients with colorectal cancer in Iran. Asian Pac J Cancer Prev 16(17):7603–7606
doi: 10.7314/APJCP.2015.16.17.7603
Nagata T, Fukuda KI, Tamai M, Taniguchi A, Kamiya H, Kambe K, Kamada Y, Iwata G, Yamaoka N (2019) Early neuropathy related to oxaliplatin treatment in advanced and recurrent colorectal cancer. Anticancer Res 39(3):1347–1353
doi: 10.21873/anticanres.13248
Takimoto CH, Graham MA, Lockwood G, Ng CM, Goetz A, Greenslade D, Remick SC, Sharma S, Mani S, Ramanathan RK, Synold TW, Doroshow JH, Hamilton A, Mulkerin DL, Ivy P, Egorin MJ, Grem JL (2007) Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res 13:4832–4839
doi: 10.1158/1078-0432.CCR-07-0475
Speck RM, DeMichele A, Farrar JT, Hennessy S, Mao JJ, Stineman MG, Barg FK (2012) Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients. Support Care Cancer 20(10):2433–2439. https://doi.org/10.1007/s00520-011-1365-8
doi: 10.1007/s00520-011-1365-8
pubmed: 22231480
Streckmann F, Zopf EM, Lehmann HC, May K, Rizza J, Zimmer P, Gollhofer A, Bloch W, Baumann FT (2014) Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 44(9):1289–1304. https://doi.org/10.1007/s40279-014-0207-5
doi: 10.1007/s40279-014-0207-5
pubmed: 24927670
Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ (2001) Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 24(3):495–499
doi: 10.2337/diacare.24.3.495
Gamelin L, Boisdron-Celle M, Delva R, Guerin-Meyer V, Ifrah N, Morel A, Gamelin E (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055–4061
doi: 10.1158/1078-0432.CCR-03-0666
Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Novotny PJ, Chitaley U, Alberts SR, Loprinzi CL (2011) Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 29:421–427
doi: 10.1200/JCO.2010.31.5911
Knijn N, Tol J, Koopman M, Werter MJ, Imholz AL, Valster FA, Mol L, Vincent AD, Teerenstra S, Punt CJ (2011) The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer 47:369–374
doi: 10.1016/j.ejca.2010.10.006
Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H (2010) Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. Int J Clin Oncol 15:82–87
doi: 10.1007/s10147-009-0015-3
Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, Seisler D, Qamar R, Lewis GC, Grothey A (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/alliance). J Clin Oncol 32:997–1005
doi: 10.1200/JCO.2013.52.0536
Aring AM, Jones DE, Falko JM (2005) Evaluation and prevention of diabetic neuropathy. Am Fam Physician 71:2123–2128
pubmed: 15952441
Ramanathan RK, Rothenberg ML, de Gramont A (2010) Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies. Ann Oncol 21:754–758
doi: 10.1093/annonc/mdp509
Grimm C, Hofstetter G, Aust S, Mutz-Dehbalaie I, Bruch M, Heinze G, Rahhal-Schupp J, Reinthaller A, Concin N, Polterauer S (2013) Association of gamma-glutamyl transferase with severity of disease at diagnosis and prognosis of ovarian cancer. Br J Cancer 109(3):610–614
doi: 10.1038/bjc.2013.323
Pandur S, Pankiv S, Johannessen M, Moens U, Huseby NE (2007) Gamma-glutamyl transferase is up regulated after oxidative stress through the Ras signal transduction pathway in rat colon carcinoma cells. Free Radic Res 41:1376–1384
doi: 10.1080/10715760701739488
Corti A, Franzini M, Paolicchi A, Pompella A (2010) Gamma-glutamyl transferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res 30:1169–1181
pubmed: 20530424
Wang J, Udd KA, Vidisheva A et al (2016) Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy. Support Care Cancer 24(7):3105–3110. https://doi.org/10.1007/s00520-016-3126-1
doi: 10.1007/s00520-016-3126-1
pubmed: 26902977
Grim J, Ticha A, Hyspler R, Valis M, Zadak Z (2017) Selected risk nutritional factors for chemotherapy-induced polyneuropathy. Nutrients 9(6):535
doi: 10.3390/nu9060535